{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:43:24Z","timestamp":1791179004856,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"DOI":"10.1093\/jac\/dki344","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T23:03:35Z","timestamp":1127257415000},"page":"914-918","source":"Crossref","is-referenced-by-count":159,"title":["Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey"],"prefix":"10.1093","volume":"56","author":[{"given":"Hande","family":"Arslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem Kurt","family":"Azap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6nder","family":"Erg\u00f6n\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Timurkaynak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,9,20]]},"reference":[{"key":"key\n\t\t\t\t20171013041312_B1","doi-asserted-by":"crossref","unstructured":"Stamm WE, Norrby RS. Urinary tract infections: disease panorama and challenges. J Infect Dis2001; 183 Suppl 1: S1\u20134.","DOI":"10.1086\/318850"},{"key":"key\n\t\t\t\t20171013041312_B2","doi-asserted-by":"crossref","unstructured":"Warren JV, Abrutyn E, Hebel R et al. Guidelines for the treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis1999; 29: 745\u201358.","DOI":"10.1086\/520427"},{"key":"key\n\t\t\t\t20171013041312_B3","doi-asserted-by":"crossref","unstructured":"Karlowsky JA, Jones ME, Thornsberry C et al. Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999. Int J Antimicrob Agents2001; 18: 121\u20137.","DOI":"10.1016\/S0924-8579(01)00369-7"},{"key":"key\n\t\t\t\t20171013041312_B4","doi-asserted-by":"crossref","unstructured":"Hryniewicz K, Szczypa K, Sulikowska A et al. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother2001; 47: 773\u201380.","DOI":"10.1093\/jac\/47.6.773"},{"key":"key\n\t\t\t\t20171013041312_B5","doi-asserted-by":"crossref","unstructured":"Zervos MJ, Hershberger E, Nicolau DP et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991\u20132000. Clin Infect Dis2003; 37: 1643\u20138.","DOI":"10.1086\/379709"},{"key":"key\n\t\t\t\t20171013041312_B6","doi-asserted-by":"crossref","unstructured":"Goettsch W, Pelt W, Nagelkerke N et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands. J Antimicrob Chemother2000; 46: 223\u20138.","DOI":"10.1093\/jac\/46.2.223"},{"key":"key\n\t\t\t\t20171013041312_B7","doi-asserted-by":"crossref","unstructured":"Karlowsky JA, Kelly LJ, Thornsberry C et al. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother2002; 46: 2540\u20135.","DOI":"10.1128\/AAC.46.8.2540-2545.2002"},{"key":"key\n\t\t\t\t20171013041312_B8","doi-asserted-by":"crossref","unstructured":"Ena J, Amador C, Martinez C et al. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin-resistant Escherichia coli. J Urol1995; 153: 117\u201320.","DOI":"10.1097\/00005392-199501000-00040"},{"key":"key\n\t\t\t\t20171013041312_B9","unstructured":"National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: 13th Informational Supplement M100-S13. NCCLS, Wayne, PA, USA, 2003."},{"key":"key\n\t\t\t\t20171013041312_B10","doi-asserted-by":"crossref","unstructured":"Steinke DT, Seaton RA, Philips G et al. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case\u2013control study with multivariate analysis for other risk factors. J Antimicrob Chemother2001; 47: 781\u20137.","DOI":"10.1093\/jac\/47.6.781"},{"key":"key\n\t\t\t\t20171013041312_B11","doi-asserted-by":"crossref","unstructured":"Alos JI, Serrano MG, Gomez-Garces JL et al. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect2005; 11: 199\u2013203.","DOI":"10.1111\/j.1469-0691.2004.01057.x"},{"key":"key\n\t\t\t\t20171013041312_B12","doi-asserted-by":"crossref","unstructured":"Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO\u00b7SENS Project. J Antimicrob Chemother2003; 51: 69\u201376.","DOI":"10.1093\/jac\/dkg028"},{"key":"key\n\t\t\t\t20171013041312_B13","doi-asserted-by":"crossref","unstructured":"Canbaz S, Peksen Y, Sunter AT et al. Antibiotic prescribing and urinary tract infection. Int J Antimicrob Agents2002; 20: 407\u201311.","DOI":"10.1016\/S0924-8579(02)00252-2"},{"key":"key\n\t\t\t\t20171013041312_B14","doi-asserted-by":"crossref","unstructured":"Hooton TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents2003; 22: S65\u2013S72.","DOI":"10.1016\/S0924-8579(03)00238-3"},{"key":"key\n\t\t\t\t20171013041312_B15","doi-asserted-by":"crossref","unstructured":"Zhanel GG, Karlowsky JA, Harding GK et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim\u2013sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin and ciprofloxacin. Antimicrob Agents Chemother2000; 44: 1089\u201392.","DOI":"10.1128\/AAC.44.4.1089-1092.2000"},{"key":"key\n\t\t\t\t20171013041312_B16","doi-asserted-by":"crossref","unstructured":"Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobial usage and resistance in community acquired Escherichia coli urinary tract infection. J Antimicrob Chemother2003; 52: 1005\u201310.","DOI":"10.1093\/jac\/dkg488"},{"key":"key\n\t\t\t\t20171013041312_B17","doi-asserted-by":"crossref","unstructured":"Howard AJ, Magee JT, Fitzgerald KA et al. Factors associated with antibiotic resistance in coliform organisms from community acquired urinary tract infection in Wales. J Antimicrob Chemother2001; 47: 305\u201313.","DOI":"10.1093\/jac\/47.3.305"},{"key":"key\n\t\t\t\t20171013041312_B18","doi-asserted-by":"crossref","unstructured":"Tolun V, K\u00fc\u00e7\u00fckbasmac\u0131 \u00d6, Akbulut DT et al. (2004). Relationship between ciprofloxacin resistance and extended-spectrum \u03b2-lactamase production in Escherichia coli and Klebsiella pneumoniae strains. Clin Microbiol Infect2004; 10: 70\u20135.","DOI":"10.1111\/j.1469-0691.2004.00723.x"},{"key":"key\n\t\t\t\t20171013041312_B19","doi-asserted-by":"crossref","unstructured":"Colodner R, Rock W, Chazan B et al. (2004). Risk factors for the development of extended-spectrum \u03b2-lactamase producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis2004; 23: 163\u20137.","DOI":"10.1007\/s10096-003-1084-2"},{"key":"key\n\t\t\t\t20171013041312_B20","doi-asserted-by":"crossref","unstructured":"Hooton TM, Besser R, Foxman B et al. (2004). Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis2004; 39: 75\u201380.","DOI":"10.1086\/422145"},{"key":"key\n\t\t\t\t20171013041312_B21","doi-asserted-by":"crossref","unstructured":"Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents2003; 22: S79\u2013S83.","DOI":"10.1016\/S0924-8579(03)00231-0"},{"key":"key\n\t\t\t\t20171013041312_B22","doi-asserted-by":"crossref","unstructured":"Minassian MA, Lewis DA, Chattopadhyay D et al. A comparison between single dose fosfomycin trometamol (Monuril\u00ae) and a 5-day course of trimethoprim in the treatment of uncomplicated urinary tract infection in women. Int J Antimicrob Agents1998; 10: 39\u201347.","DOI":"10.1016\/S0924-8579(98)00021-1"},{"key":"key\n\t\t\t\t20171013041312_B23","doi-asserted-by":"crossref","unstructured":"Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther1999; 21: 1864\u201372.","DOI":"10.1016\/S0149-2918(00)86734-X"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/56\/5\/914\/2654650\/dki344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T04:24:57Z","timestamp":1507868697000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/56\/5\/914\/893198\/Risk-factors-for-ciprofloxacin-resistance-among"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,20]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,9,20]]},"published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki344","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,11]]},"published":{"date-parts":[[2005,9,20]]}}}